Clinical Trials
71 trialsTIBET
Borstkanker Onderzoek Groep
SEQUEL-Breast
Borstkanker Onderzoek Groep
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
Eastern Cooperative Oncology Group
Appalaches
European Organisation for Research and Treatment of Cancer - EORTC
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Canadian Cancer Trials Group
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Eastern Cooperative Oncology Group
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
Eastern Cooperative Oncology Group
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Eastern Cooperative Oncology Group
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
PREcoopERA
ETOP IBCSG Partners Foundation
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
Canadian Cancer Trials Group
CFI-400945 in Patients With Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
NEOLBC
Borstkanker Onderzoek Groep
TRAIN-3
Borstkanker Onderzoek Groep
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Proton Collaborative Group
Proton Radiation for Stage II/III Breast Cancer
Proton Collaborative Group
TOUCH
ETOP IBCSG Partners Foundation
Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)
Cancer Trials Ireland
Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
PYTHIA
ETOP IBCSG Partners Foundation
METEORA-II
ETOP IBCSG Partners Foundation
Chemo-free BRCA-targeted Neoadjuvant Strategy
European Organisation for Research and Treatment of Cancer - EORTC
Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Canadian Cancer Trials Group
Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer
Canadian Cancer Trials Group
OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
Canadian Cancer Trials Group
IND197
Canadian Cancer Trials Group
A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
Eastern Cooperative Oncology Group
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
Eastern Cooperative Oncology Group
Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer
Eastern Cooperative Oncology Group
Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer
Eastern Cooperative Oncology Group
FB-12
NSABP Foundation Inc
Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1
European Organisation for Research and Treatment of Cancer - EORTC
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery
Radiation Therapy Oncology Group
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
NSABP Foundation Inc
PALLET
NSABP Foundation Inc
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
NSABP Foundation Inc
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
NSABP Foundation Inc
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
NSABP Foundation Inc
Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer
NSABP Foundation Inc
Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density
Canadian Cancer Trials Group
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
GOG Foundation
PERIDENO
Borstkanker Onderzoek Groep
TREND
ETOP IBCSG Partners Foundation
TREAT-CTC
European Organisation for Research and Treatment of Cancer - EORTC
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
SWOG Cancer Research Network
TCHL Phase II
Cancer Trials Ireland
S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone
SWOG Cancer Research Network
S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
SWOG Cancer Research Network
neurabrax
Fundacion Oncosur